B-type natriuretic peptide single nucleotide polymorphism rs198389 is highly prevalent and impacts test characteristics of common assays by Lisa C Costello-Boerrigter et al.
BioMed CentralBMC Pharmacology
ssOpen AccePoster presentation
B-type natriuretic peptide single nucleotide polymorphism 
rs198389 is highly prevalent and impacts test characteristics of 
common assays
Lisa C Costello-Boerrigter*1, Guido Boerrigter1, Syed Ameenuddin1, 
Douglas W Mahoney3, Joshua P Susser4, Denise M Heublein1, 
Margaret M Redfield1, Richard J Rodeheffer2, Timothy M Olson5 and 
John C Burnett Jr1
Address: 1Cardiorenal Research Laboratory and Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, 
Minnesota, USA, 2Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota, USA, 3Division 
of Epidemiology, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota, USA, 4Division of Biostatistics, Mayo Clinic and Mayo 
Clinic College of Medicine, Rochester, Minnesota, USA and 5Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, 
Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Email: Lisa C Costello-Boerrigter* - costello.lisa@mayo.edu
* Corresponding author    
Background
BNP assays are widely used in the diagnosis and prognosis
of left ventricular (LV) dysfunction and heart failure. The
functional single nucleotide polymorphism rs198389 in
the promoter region of the BNP gene has been associated
with higher BNP levels [1-3]. The prevalence of rs198389
in the general US population is unknown. The impact on
common assay test characteristics, and cardiovascular and
clinical phenotypes is also unknown. The goal of this
study was to determine for the first time the prevalence of
rs198389 in a US general adult population and its impact
on (a) three commonly used BNP assays (BNP levels,
diagnostic test performance), and (b) clinical phenotype
and disease prevalence.
Materials and methods
A random sample of the general population (≥ 45 years; n
= 1970) from Olmsted County, MN, USA was genotyped
for rs198389, BNP plasma levels (Biosite, Shionogi, and
Roche NT-proBNP assays) were determined, and detailed
biochemical, clinical, and echocardiographic characteri-
zations were performed. The effect of rs198389 on plasma
BNP and NT-proBNP assay test characteristics for the
detection of LV dysfunction was evaluated.
Results
Genotype frequencies were in Hardy-Weinberg equilib-
rium (p = 0.98): TT 32.7%, TC 49.9%, and CC 17.3%. The
C-allele independently predicted higher BNP in multivar-
iate analysis (p < 0.0001 for all assays). When using previ-
ously reported genotype-unadjusted cutpoints for the
detection of LV ejection fraction ≤ 40% and ≤ 50%, sensi-
tivity increased with the number of C-alleles (approxi-
mately 10% for CC vs TT), whereas specificity decreased
(approximately 10% for CC vs TT). C-alleles were associ-
ated with higher prevalence of type 2 diabetes mellitus
(OR: 1.63 (CI: 1.09–2.44), p = 0.02, dominant model)
and atrial fibrillation (OR: 1.63 (CI: 1.01–2.63), p = 0.04,
recessive model).
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rs198389 is common in the general US population. The
C-allele is associated with higher plasma BNP and con-
founds the test characteristics of commonly used assays.
The association of rs198389 with diabetes and atrial fibril-
lation needs to be confirmed and further explored.
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